Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
80 hedge funds and large institutions have $456M invested in Chinook Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 80 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71% less call options, than puts
Call options by funds: $66K | Put options by funds: $231K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$171M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$69.6M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$38M |
| 4 |
O
OrbiMed
New York
|
+$35.2M |
| 5 |
Jennison Associates
New York
|
+$24.8M |
Top Sellers
KDNY Hedge Fund Activity: Q2 2015 in Review
80 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q2 2015, worth a combined $456M.
Buyers outnumbered sellers: 80 funds opened new KDNY positions and 0 closed out — a net gain of 80 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $171M.
- 80 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $456M of Chinook Therapeutics, Inc. Common Stock stock for Q2 2015.
- 80 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q2 2015 and 0 closed out, a net change of +80 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q2 2015 was Fidelity Investments, an estimated $171M added.
Based on aggregated 13F filings for Q2 2015.